David H Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Would also highlight an IST run by Tian Zhang at UTSW is evaluating Enfortumab Vedotin + RT for cisplatin-ineligible patients with MIBC. Variant mixed histology tumors are included in this trial.
More about variant histologies here at Uromigos.
Quick review of variant histology UC here.”
Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, shared this post, adding:
“Thanks for highlighting, David H Aggen!
Indeed we have added variant histos for the STAREV trial! Trying to drive path CR w EV, radiation then surgery!
Open and enrolling.”
More posts featuring Tian Zhang.